AGENUS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AGENUS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $8.35M | Mar 16, 2018 |
| FY2017 | Sep 30, 2017 | $3.36M | Mar 16, 2018 |
| FY2017 | Jun 30, 2017 | $4.21M | Mar 16, 2018 |
| FY2017 | Mar 31, 2017 | $26.96M | Mar 16, 2018 |
| FY2017 | Dec 31, 2016 | $5.58M | Mar 16, 2018 |
| FY2017 | Sep 30, 2016 | $4.45M | Mar 16, 2018 |
| FY2017 | Jun 30, 2016 | $6.59M | Mar 16, 2018 |
| FY2017 | Mar 31, 2016 | $5.96M | Mar 16, 2018 |
| FY2016 | Dec 31, 2015 | $7.64M | Mar 16, 2017 |
| FY2016 | Sep 30, 2015 | $6.85M | Mar 16, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.20M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $103.46M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $156.31M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $98.02M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $295.67M | Mar 14, 2024 |
| FY2020 | Dec 31, 2020 | $31.27M | Mar 16, 2021 |
| FY2020 | Sep 30, 2020 | $14.83M | Mar 16, 2021 |
| FY2020 | Jun 30, 2020 | $26.95M | Mar 16, 2021 |
| FY2020 | Mar 31, 2020 | $15.13M | Mar 16, 2021 |
| FY2020 | Dec 31, 2019 | $34.50M | Mar 16, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | ($37.73M) | Mar 16, 2021 |
| FY2020 | Sep 30, 2020 | ($51.65M) | Mar 16, 2021 |
| FY2020 | Jun 30, 2020 | ($48.24M) | Mar 16, 2021 |
| FY2020 | Mar 31, 2020 | ($45.27M) | Mar 16, 2021 |
| FY2020 | Dec 31, 2019 | ($30.85M) | Mar 16, 2021 |
| FY2020 | Sep 30, 2019 | ($46.28M) | Mar 16, 2021 |
| FY2020 | Jun 30, 2019 | ($51.87M) | Mar 16, 2021 |
| FY2020 | Mar 31, 2019 | $17.44M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($48.85M) | Mar 16, 2020 |
| FY2019 | Sep 30, 2018 | ($33.73M) | Mar 16, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($20.17M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($120.48M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($159.55M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($179.43M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $25.75M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($117.24M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($70.14M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | ($123.82M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | ($103.80M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | ($107.48M) | Mar 18, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $79.34M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $155.53M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $234.57M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $186.69M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $178.61M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $142.62M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $168.34M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $124.60M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $116.13M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $94.97M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($77.20M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($158.32M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | ($224.20M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | ($175.37M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $10.15M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($139.10M) | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | ($18.68M) | Mar 1, 2022 |
| FY2018 | Dec 31, 2018 | ($35.80M) | Mar 18, 2019 |
| FY2018 | Sep 30, 2018 | ($24.60M) | Mar 18, 2019 |
| FY2018 | Jun 30, 2018 | ($30.50M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $576.0K | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $9.95M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $53.06M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $33.81M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $3.47M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $4.66M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $3.60M | Mar 16, 2021 |
| FY2019 | Dec 31, 2017 | $3.12M | Mar 16, 2020 |
| FY2018 | Dec 31, 2016 | $12.52M | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.80M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $226.27M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $313.91M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $413.56M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $465.96M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $214.51M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $155.34M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $136.40M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $138.40M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $156.99M | Mar 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($271.11M) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($326.38M) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($160.33M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($61.28M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $34.44M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($203.67M) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($225.36M) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($172.47M) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($75.82M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($39.13M) | Mar 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $24.09M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $24.09M | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | $24.72M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $25.47M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $24.88M | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | $25.45M | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | $23.19M | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | $22.93M | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | $23.05M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $22.39M | Mar 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.18B) | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | ($2.18B) | Mar 16, 2026 |
| FY2024 | Dec 31, 2023 | ($1.96B) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($1.71B) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($1.49B) | Mar 16, 2023 |
| FY2021 | Dec 31, 2020 | ($1.47B) | Mar 1, 2022 |
| FY2020 | Dec 31, 2019 | ($1.28B) | Mar 16, 2021 |
| FY2019 | Dec 31, 2018 | ($1.18B) | Mar 16, 2020 |
| FY2018 | Dec 31, 2017 | ($1.03B) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($905.33M) | Mar 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.00M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $40.44M | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | $76.11M | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | $178.67M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $291.93M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $99.87M | Mar 16, 2023 |
| FY2021 | Dec 31, 2019 | $61.81M | Mar 1, 2022 |
| FY2020 | Dec 31, 2018 | $53.05M | Mar 16, 2021 |
| FY2018 | Dec 31, 2017 | $60.19M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $71.45M | Mar 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $44.66M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | $33.17M | Mar 16, 2026 |
| FY2015 | Dec 31, 2015 | $114.47M | Mar 15, 2016 |
| FY2015 | Dec 31, 2014 | $6.03M | Mar 15, 2016 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (13) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (15) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Mar 16, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | (10) | Mar 16, 2026 |
| FY2025 | Dec 31, 2023 | (13) | Mar 16, 2026 |
| FY2024 | Dec 31, 2022 | (15) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | (1) | Mar 16, 2023 |
| FY2020 | Dec 31, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Sep 30, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Jun 30, 2019 | 0 | Mar 16, 2021 |
| FY2020 | Mar 31, 2019 | 0 | Mar 16, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 35.32M | Mar 16, 2026 |
| FY2025 | Dec 31, 2024 | 23.63M | Mar 16, 2026 |